These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Vosper H Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285 [TBL] [Abstract][Full Text] [Related]
25. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice. Li Z; Blad CC; van der Sluis RJ; de Vries H; Van Berkel TJ; Ijzerman AP; Hoekstra M Br J Pharmacol; 2012 Oct; 167(4):818-25. PubMed ID: 22616721 [TBL] [Abstract][Full Text] [Related]
26. Niacin: an old drug rejuvenated. Kamanna VS; Ganji SH; Kashyap ML Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727 [TBL] [Abstract][Full Text] [Related]
27. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Davidson MH Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236 [TBL] [Abstract][Full Text] [Related]
28. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. Keenan JM J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578 [TBL] [Abstract][Full Text] [Related]
29. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis. Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616 [TBL] [Abstract][Full Text] [Related]
30. Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing. Sakurai T; Davenport R; Stafford S; Grosse J; Ogawa K; Cameron J; Parton L; Sykes A; Mack S; Bousba S; Parmar A; Harrison D; Dickson L; Leveridge M; Matsui J; Barnes M Eur J Pharmacol; 2014 Mar; 727():1-7. PubMed ID: 24486398 [TBL] [Abstract][Full Text] [Related]
31. A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia. Olson EJ; Mahar KM; Haws TF; Fossler MJ; Gao F; de Gouville AC; Sprecher DL; Lepore JJ Clin Pharmacol Drug Dev; 2019 Oct; 8(7):871-883. PubMed ID: 31268250 [TBL] [Abstract][Full Text] [Related]
32. Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution. Yadav MK; Sarma P; Maharana J; Ganguly M; Mishra S; Zaidi N; Dalal A; Singh V; Saha S; Mahajan G; Sharma S; Chami M; Banerjee R; Shukla AK Nat Commun; 2024 Mar; 15(1):1939. PubMed ID: 38431681 [TBL] [Abstract][Full Text] [Related]
37. Protective effects of lipoic acid-niacin dimers against blue light-induced oxidative damage to retinal pigment epithelium cells. Zou XL; Yu YZ; Yu HH; Wang GF; Pi RB; Xu Z; Zhang C; Zhou WJ; Li DD; Chen XG; Zou YP Int J Ophthalmol; 2019; 12(8):1262-1271. PubMed ID: 31456915 [TBL] [Abstract][Full Text] [Related]
38. Future of GPR109A agonists in the treatment of dyslipidaemia. Wanders D; Judd RL Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500 [TBL] [Abstract][Full Text] [Related]
39. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324 [TBL] [Abstract][Full Text] [Related]
40. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]